circFAT1 Promotes Cancer Stemness and Immune Evasion by Promoting STAT3 Activation-Reference-Cited by-同舟云学术

circFAT1 Promotes Cancer Stemness and Immune Evasion by Promoting STAT3 Activation

Published:2021-05-02 Issue:13 Volume:8 Page:2003376
ISSN:2198-3844
Container-title:Advanced Science
language:en
Short-container-title:Adv. Sci.

Author:

Jia Lingfei¹²,Wang Yilun¹²,Wang Cun‐Yu¹²³^ORCID

Affiliation:

1. Jonsson Comprehensive Cancer Center UCLA Los Angeles CA 90095 USA

2. Laboratory of Molecular Signaling Division of Oral Biology and Medicine School of Dentistry UCLA Los Angeles CA 90095 USA

3. Department of Bioengineering Henry Samueli School of Engineering and Applied Science UCLA Los Angeles CA 90095 USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

General Physics and Astronomy,General Engineering,Biochemistry, Genetics and Molecular Biology (miscellaneous),General Materials Science,General Chemical Engineering,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/advs.202003376

Reference46 articles.

1. Global Cancer Statistics, 2002

2. Pathways for cervical metastasis in malignant neoplasms of the head and neck region

3. An update: emerging drugs to treat squamous cell carcinomas of the head and neck

4. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma

5. Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Crosstalk between circular RNAs and the STAT3 signaling pathway in human cancer;Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms;2024-12

2. Interplay between JAK/STAT pathway and non-coding RNAs in different cancers;Non-coding RNA Research;2024-12

3. CircPGM5 regulates Foxo3a phosphorylation via MiR-21-5p/MAPK10 axis to inhibit bladder cancer progression;Cellular Signalling;2024-09

4. Circular RNAs in tumor immunity and immunotherapy;Molecular Cancer;2024-08-21

5. Head and neck cancer: pathogenesis and targeted therapy;MedComm;2024-08-21